Search Results - "Hochmair, M.J." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)

Treatment duration of brigatinib in patients enrolled in the international expanded access program (EAP)

by Lin, M.M., Pan, X., Hou, P., Allen, S., Baumann, P., Hochmair, M.J.
Published in Annals of oncology (01.04.2019)

Get full text

Journal Article

$Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review$

Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review

by Ansari, Jawaher, Eltigani Mohmmed, Yussra, Ghazal-Aswad, Saad, Ansari, Hidayath, Akhter, Syed M.J., Hassoun Hadid, Omar, Rizwan, Syed, Almazrouei, Raya, Dawoud, Emad, Azribi, Fathi, Elhasin, Heba, Kumar, Pawan, Al Sumaida, Abdul Rahman, Al-Qawasmeh, Khaled, Glaholm, John, Hochmair, M.J., Hussain, Syed, Balaraj, Khalid
Published in Gynecologic oncology reports (01.11.2021)

Get full text

Journal Article

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

FP13.02 Pembrolizumab + Pemetrexed-Platinum vs Pemetrexed-Platinum for Metastatic NSCLC: 4-Year Follow-up From KEYNOTE-189

by Gray, J., Rodríguez-Abreu, D., Powell, S.F., Hochmair, M.J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S.Y., Bischoff, H.G., Peled, N., Reck, M., Hui, R., Garon, E.B., Boyer, M., Kurata, T., Yang, J., Jensen, E., Souza, F., Garassino, M.C.
Published in Journal of thoracic oncology (01.03.2021)

Get full text

Journal Article

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189

by Rodríguez-Abreu, D., Powell, S.F., Hochmair, M.J., Gadgeel, S., Esteban, E., Felip, E., Speranza, G., De Angelis, F., Dómine, M., Cheng, S.Y., Bischoff, H.G., Peled, N., Reck, M., Hui, R., Garon, E.B., Boyer, M., Kurata, T., Yang, J., Pietanza, M.C., Souza, F., Garassino, M.C.
Published in Annals of oncology (01.07.2021)

Get full text

Journal Article

Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib

Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib

by Buder, A., Hochmair, M.J., Setinek, U., Filipits, M.
Published in Annals of oncology (01.11.2019)

Get full text

Journal Article

Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC

Mutation tracking in circulating tumour DNA predicts relapse in completely resected EGFR-mutated NSCLC

by Filipits, M., Hochmair, M.J., Buder, A., Watzka, S.
Published in Annals of oncology (01.11.2019)

Get full text

Journal Article

38P Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)

38P Matching-adjusted indirect comparison (MAIC) of treatment outcomes for selective RET inhibitors, selpercatinib and pralsetinib, in non-small cell lung cancer (NSCLC)

by Hochmair, M.J., Nadal, E., D’yachkova, Y., Puri, T., Vickers, A., Wolowacz, S., Wang, X., Kiiskinen, U.
Published in Journal of thoracic oncology (01.04.2023)

Get full text

Journal Article

55P Comparison of BiomeOne and PD-L1 expression tests as a predictor for response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC)

55P Comparison of BiomeOne and PD-L1 expression tests as a predictor for response to immune checkpoint inhibitors (ICI) in patients with non-small cell lung cancer (NSCLC)

by Robinson, I., Hochmair, M.J., Ay, L., Absenger, G., Jansen, C., Pacifico, C., Sladek, B., Knabl, A., Gasche, N., Valipour, A.
Published in Annals of oncology (01.10.2022)

Get full text

Journal Article

LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial

LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial

by Reck, M., Gale, D., Harpole, D., Taube, J.M., Mitsudomi, T., Hochmair, M.J., Winder, T., Zhu, Z., Lai, Z., Stewart, R., Hodgson, D.R., Doherty, G.J., Heymach, J.V.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy

117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy

by Robinson, I., Schmidinger, M., Hochmair, M.J., Ay, L., Absenger, G., Pichler, M., Nguyen, V.A.F., Richtig, E., Rainer, B., Jansen, C., Sladek, B., Knabl, A., Gasche, N., Valipour, A.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article

1417P - Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

1417P - Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

by Grech, C., Hackner, K., Strieder, M., Buder, A., Hochmair, M.J., Filipits, M., Errhalt, P.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

Analysis of circulating tumour DNA in paired plasma and sputum samples of EGFR-mutated NSCLC patients

by Grech, C., Hackner, K., Strieder, M., Buder, A., Hochmair, M.J., Filipits, M., Errhalt, P.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC

by Jänne, P.A., Wang, B-C., Cho, B.C., Zhao, J., Li, J., Hochmair, M.J., Peters, S., Besse, B., Kato, T., Wu, Y-L., Nguyen, D., Lin, J., Vranceanu, F., Lin, M., Fram, R.J., Mok, T.S.K.
Published in Annals of oncology (01.11.2023)

Get full text

Journal Article

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

by Garassino, M.C., Theelen, W.S.M.E., Jotte, R., Laskin, J., de Marinis, F., Aguado, C., Badin, F.B., Chmielewska, I., Hochmair, M.J., Lu, S., Nadal, E., Ostoros, G., Felip, E., Spira, A.I., Lane, C.M., He, J., Chao, R., Jänne, P.A.
Published in Annals of oncology (01.10.2023)

Get full text

Journal Article

PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)

PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)

by Sabari, J., Kim, T.M., Spira, A., Lee, S.H., Chang, G.C., Shih, J.-Y., Hochmair, M.J., Schioppa, C.A., Schioppa, C.A., Panaccione, A., Rose, J.B., Chioda, M., Mahadevia, P., Cho, B.C.
Published in Journal of thoracic oncology (01.03.2023)

Get full text

Journal Article

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

by Paz-Ares, L., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Voitko, O., Poltoratskiy, A., Musso, E., Havel, L., Bondarenko, I., Losonczy, G., Conev, N., Mann, H., Dalvi, T.B., Jiang, H., Goldman, J.W.
Published in ESMO open (01.04.2022)

Get full text

Journal Article

1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)

1279P The prognostic value of chemotherapy-induced neutropenia (CIN) in patients with advanced non-small cell lung cancer (NSCLC) in the era of chemoimmunotherapy (CIT)

by Meisel, A., Mark, M.T., Haider, A., Holer, L., Hayoz, S., Gebhard, C., Bengs, S., Hochmair, M.J., Cappuzzo, F., Reck, M., von Moos, R., Stenner-Liewen, F.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

1223P Sequential afatinib (afa) and osimertinib (osi) in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC who acquire the T790M resistance mutation: A non-interventional cohort study (UpSwinG)

by Popat, S., Jung, H.A., Lee, S. Yup, Hochmair, M.J., Lee, S.H., Escriu, C., Lee, M.K., Migliorino, M.R., Lee, Y.C., Girard, N., Daoud, H., Märten, A., Miura, S.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

EP02.01-008 Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

by Zacharias, M., Konjic, S., Absenger, G., Hochmair, M.J., Fabikan, H., Weinlinger, C., Illini, O., Jost, P.J., Schlintl, V., Wurm, R., Lindenmann, J., Fediuk, M., Brcic, L., Terbuch, A.
Published in Journal of thoracic oncology (01.09.2022)

Get full text

Journal Article

1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

1530P Durvalumab (D) + platinum-etoposide (EP) in first-line extensive-stage SCLC (ES SCLC): Effect of age and platinum agent on outcomes in CASPIAN

by Reinmuth, N., Goldman, J.W., Chen, Y., Hotta, K., Statsenko, G., Hochmair, M.J., Özgüroğlu, M., Ji, J.H., Garassino, M.C., Poltoratskiy, A., Verderame, F., Havel, L., Bondarenko, I., Losonczy, G., Conev, N.V., Mann, H., Chugh, P., Dalvi, T.B., Paz-Ares, L.
Published in Annals of oncology (01.09.2022)

Get full text

Journal Article